RU2715734C2 - Схема дозирования модулятора s1p с немедленным высвобождением - Google Patents

Схема дозирования модулятора s1p с немедленным высвобождением Download PDF

Info

Publication number
RU2715734C2
RU2715734C2 RU2016143979A RU2016143979A RU2715734C2 RU 2715734 C2 RU2715734 C2 RU 2715734C2 RU 2016143979 A RU2016143979 A RU 2016143979A RU 2016143979 A RU2016143979 A RU 2016143979A RU 2715734 C2 RU2715734 C2 RU 2715734C2
Authority
RU
Russia
Prior art keywords
siponimod
dosage form
patients
day
per day
Prior art date
Application number
RU2016143979A
Other languages
English (en)
Russian (ru)
Other versions
RU2016143979A (ru
RU2016143979A3 (cg-RX-API-DMAC7.html
Inventor
Эрик ЛЕГАНЬНЕ
Эрик Валлстрём
Филипп Мишель Рене Буйо
Эмерик Рейно
Франк ДАЛЬКЕ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2715734(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2016143979A publication Critical patent/RU2016143979A/ru
Publication of RU2016143979A3 publication Critical patent/RU2016143979A3/ru
Application granted granted Critical
Publication of RU2715734C2 publication Critical patent/RU2715734C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016143979A 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением RU2715734C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020107732A Division RU2020107732A (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Publications (3)

Publication Number Publication Date
RU2016143979A RU2016143979A (ru) 2018-05-14
RU2016143979A3 RU2016143979A3 (cg-RX-API-DMAC7.html) 2018-11-12
RU2715734C2 true RU2715734C2 (ru) 2020-03-03

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016143979A RU2715734C2 (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением
RU2020107732A RU2020107732A (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020107732A RU2020107732A (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Country Status (16)

Country Link
US (4) US20170027907A1 (cg-RX-API-DMAC7.html)
EP (3) EP3129020A1 (cg-RX-API-DMAC7.html)
JP (1) JP6674903B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160141841A (cg-RX-API-DMAC7.html)
CN (2) CN116650467A (cg-RX-API-DMAC7.html)
AU (2) AU2015246036A1 (cg-RX-API-DMAC7.html)
CA (1) CA2943598C (cg-RX-API-DMAC7.html)
CL (1) CL2016002562A1 (cg-RX-API-DMAC7.html)
IL (2) IL305337A (cg-RX-API-DMAC7.html)
MX (1) MX2016013245A (cg-RX-API-DMAC7.html)
PH (1) PH12016501965A1 (cg-RX-API-DMAC7.html)
RU (2) RU2715734C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201607894RA (cg-RX-API-DMAC7.html)
TW (1) TW201622721A (cg-RX-API-DMAC7.html)
WO (1) WO2015155709A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606519B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
CN111107845A (zh) * 2017-09-29 2020-05-05 诺华股份有限公司 西尼莫德的给药方案
ES3011730T3 (en) * 2018-03-01 2025-04-08 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
EP3823627A4 (en) 2018-07-17 2022-04-20 Insmed Incorporated CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2024148308A1 (en) 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2012093161A1 (en) * 2011-01-07 2012-07-12 Novartis Ag Immunosuppressant formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2379497T1 (sl) * 2008-12-18 2013-12-31 Novartis Ag Hemifumaratna sol 1-(4-(1-(4-ciklohaksil-3-trifluorometil-benziloksiimino)-etil)-2-etil- benzil)azetidin-3-karboksilne kisline
HUE026869T2 (en) * 2008-12-22 2016-08-29 Novartis Ag Dosage regimen for fingolimod for the treatment of multiple sclerosis
CN103933570A (zh) * 2009-09-29 2014-07-23 诺华股份有限公司 S1p受体调节剂的给药方案
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
SG10201602279PA (en) * 2011-10-21 2016-04-28 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2012093161A1 (en) * 2011-01-07 2012-07-12 Novartis Ag Immunosuppressant formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPPOS L. et ak. Siponimod (BAF312) for the Treatmebt of Secondary Progressive Multiple Sclerosis: Design of the phase 3 EXPAND trial. // Neurology, 2013, 80:1, Abstract, найдено он-лайн в базе данных Embase. *
KRZYSZTOF SELMAJ ET AL, "Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study", THE LANCET NEUROLOGY, (20130801), vol. 12, no. 8, pages 756-767, abstrast. *

Also Published As

Publication number Publication date
ZA201606519B (en) 2017-11-29
IL247986A0 (en) 2016-11-30
EP3129020A1 (en) 2017-02-15
CL2016002562A1 (es) 2017-07-28
AU2020203107A1 (en) 2020-05-28
RU2016143979A (ru) 2018-05-14
US20170027907A1 (en) 2017-02-02
IL305337A (en) 2023-10-01
RU2020107732A (ru) 2020-03-30
PH12016501965A1 (en) 2017-01-09
US20190054065A1 (en) 2019-02-21
RU2016143979A3 (cg-RX-API-DMAC7.html) 2018-11-12
KR20220156981A (ko) 2022-11-28
JP2017510607A (ja) 2017-04-13
WO2015155709A1 (en) 2015-10-15
EP3831378A1 (en) 2021-06-09
KR20160141841A (ko) 2016-12-09
US20220016076A1 (en) 2022-01-20
CA2943598A1 (en) 2015-10-15
CN116650467A (zh) 2023-08-29
SG11201607894RA (en) 2016-10-28
CA2943598C (en) 2023-03-07
AU2015246036A1 (en) 2016-10-13
MX2016013245A (es) 2017-01-16
JP6674903B2 (ja) 2020-04-01
TW201622721A (zh) 2016-07-01
AU2020203107B2 (en) 2021-10-21
US20250041266A1 (en) 2025-02-06
EP4074312A1 (en) 2022-10-19
CN106456552A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
RU2715734C2 (ru) Схема дозирования модулятора s1p с немедленным высвобождением
US20230355577A1 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
BG65677B1 (bg) Използване на дапоксетин, бързодействащ реактивен серотонинов инхибитор за лечение на сексуална дисфункция
TW202131910A (zh) 使用mtorc1調節劑的治療方法
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
KR20250095747A (ko) 과민성 방광의 치료를 위한 비베그론의 투약
US20070185080A1 (en) Pharmaceutical Compositions
JP2004525941A (ja) 治療方法
US20110027324A1 (en) O-desmethyl-venlafaxine for treating major depressive disorder
JP2008255064A (ja) 睡眠障害予防治療剤
CN101507726A (zh) 窦房结If电流抑制剂和β-阻滞剂的组合
JP6042886B2 (ja) 早漏症治療用の薬学組成物
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
TW202527911A (zh) 用於治療猝睡症的化合物
WO2011051423A1 (en) Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190312

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20190523